TRINETRA › Sectors › Healthcare
Sun Pharma Advanced Research Company Limited (SPARC) — share price, P/E and fundamentals
Sun Pharma Advanced Research Company Limited (NSE: SPARC) closed at ₹176.46 on 30 Oct 2026, +36.4% over one year, against a 52-week range of ₹108.00 – ₹289.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 10 Aug 2026) it reported revenue of ₹40 cr and a net loss of ₹21 cr, a -52.0% net margin; revenue grew 314.1% year on year.
On four consecutive filed quarters its trailing P/E is 3.6.
From the balance sheet dated 31 Mar 2026: return on equity -6.2%, ROCE -3.5%, debt-to-equity 0.42, Piotroski F-score 7 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 0% of 63 sector peers; PBT margin higher than 0% of 63 sector peers; ROE higher than 2% of 63 sector peers.
Key figures
| Last close | ₹176.46 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -13.5% / +26.7% / +36.4% |
| 52-week low – high | ₹108.00 – ₹289.00 |
| Market capitalisation | ₹5,726 cr |
| Trailing P/E | 3.6 |
| Price / book | 4.28 |
| EV / EBITDA | 3.9 |
| Earnings yield | 27.7% |
| TTM EPS | ₹48.82 |
| TTM net profit | ₹1,584 cr |
| Quarter revenue | ₹40 cr |
| Quarter net loss | ₹21 cr |
| Net margin | -52.0% |
| Revenue growth (YoY) | +314.1% |
| Profit growth (YoY) | +60.1% |
| Return on equity | -6.2% |
| ROCE | -3.5% |
| Debt / equity | 0.42 |
| Current ratio | 2.47 |
| Free cash flow | ₹-263 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹14.3 cr |
Against Healthcare peers
| Metric | SPARC | Peer median | Percentile |
|---|---|---|---|
| Net margin | -52.00 | 12.89 | 0 |
| PBT margin | -51.78 | 17.68 | 0 |
| ROE | -6.20 | 13.87 | 2 |
| ROCE | -3.54 | 17.26 | 2 |
| Debt / equity | 0.42 | 0.11 | 81 |
| Cash conversion | -0.15 | 1.25 | 2 |
| Trailing P/E | 3.61 | 43.26 | 0 |
| P/B | 4.28 | 6.02 | 29 |
Questions
What is the P/E ratio of Sun Pharma Advanced Research Company Limited?
Sun Pharma Advanced Research Company Limited's trailing P/E is 3.6, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026.
What were Sun Pharma Advanced Research Company Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Sun Pharma Advanced Research Company Limited reported revenue of ₹40 cr and a net loss of ₹21 cr (consolidated), filed with the exchange on 10 Aug 2026.
What is Sun Pharma Advanced Research Company Limited's ROE?
Return on equity is -6.2% based on the balance sheet dated 31 Mar 2026.
Does Sun Pharma Advanced Research Company Limited have debt?
Debt-to-equity is 0.42 on the balance sheet dated 31 Mar 2026.
What is SPARC's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, SPARC traded between ₹108.00 and ₹289.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.